We have an eye on novel platforms for improving translation of Investigative New Drug therapies in efficient and cost-effective manner.

Founders of Eyescreen, Inc. have worked tirelessly for over 5 years to establish infrastructure, approaches and technology for procuring, transporting, reviving and preserving light responses in the human retina like they would be in a living human being. This work culminated in a groundbreaking study that was published in Nature by Dr. Vinberg (Abbas et al., 2022, Nature). Based on these findings, we have developed technology and approaches for testing the neuroprotective, antioxidative and anti-inflammatory potential of drug molecules in “living” human retina tissue, something that was not possible before in a preclinical setting. We are also developing ways to test delivery of gene therapies in the ex-situ human eyes e.g. via subretinal and intravitreal injections. We are excited to collaborate with Pharma and Academia to advance development of new drug and gene therapies targeting ischemic and degenerative retinal or brain diseases.